{"id":32971,"date":"2023-01-09T18:18:26","date_gmt":"2023-01-09T13:18:26","guid":{"rendered":"http:\/\/myanmarnewsgazette.com\/?guid=9513aa8fd556b188e2f7d1ddb947f62b"},"modified":"2023-01-09T18:18:26","modified_gmt":"2023-01-09T13:18:26","slug":"ena-respiratory-awarded-4-38-million-u-s-department-of-defense-agreement-to-fund-development-of-broad-spectrum-antiviral-inna-051","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/ena-respiratory-awarded-4-38-million-u-s-department-of-defense-agreement-to-fund-development-of-broad-spectrum-antiviral-inna-051\/","title":{"rendered":"ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051"},"content":{"rendered":"

— Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats<\/em><\/p>\n

MELBOURNE, Australia, Jan. 09, 2023 (GLOBE NEWSWIRE) — Clinical-stage pharmaceutical company\u00a0ENA Respiratory<\/a>\u00a0has been awarded a $4.38 million USD agreement from the U.S. Department of Defense (DoD) to support ongoing research and development of INNA-051, a clinical stage first-in-class broad-spectrum antiviral innate immunomodulator, administered intranasally for the prophylaxis of respiratory viral infections and their complications.<\/p>\n

The agreement was awarded by the DoD\u2019s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in collaboration with the Defense Innovation Unit (DIU). Funding will support studies to develop an intranasal dry powder formulation of INNA-051 and scale-up manufacturing processes.<\/p>\n

\u201cPopulations at high risk of exposure or complications continue to be significantly affected by influenza, SARS-CoV-2, RSV and other respiratory viruses, driving increased hospitalizations and health care utilization,\u201d said Christophe Demaison, Ph.D., co-founder and CEO of ENA Respiratory. \u201cThis agreement with the DoD recognizes the necessity of developing a broad-spectrum and fast-acting treatment to combat these debilitating viruses, and studying its use across a range of critical populations.\u201d<\/p>\n

The effort is expected to run for 12 months, paving the way to an Investigational New Drug (IND)-submission to the U.S. FDA aiming to support the Phase I bioequivalence study of an intranasal dry powder presentation of INNA-051. A dry powder formulation offers a number of advantages over the current spray solution formulation that will support deployment to distant or resource-limited settings and survival through the rigours of DoD logistics. INNA-051 was recently studied in a Phase 2a influenza challenge pre-exposure prophylaxis study, and results are expected soon. It was found to be well-tolerated in a Phase 1 study.<\/p>\n

Effort funded by the U.S. Department of Defense\u2019s Chemical and Biological Defense Program (CBDP), under Other Transaction Authority number HQ0845-23-9-0003 between ENA Respiratory Pty Ltd and the DoD. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon.<\/em><\/p>\n

The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government or the U.S. Department of Defense.<\/em><\/p>\n

ENDS<\/strong><\/p>\n

Notes to Editors<\/strong><\/p>\n

If you would like to arrange an interview, please contact:<\/p>\n